TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean difference in maximum increment value of insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: daily steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accuracy of FDG-PET/MRI for nodal metastases detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of any atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radioactivity in whole blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Pharmacokinetics of OSI-906 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Pharmacokinetics of OSI-906 in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of an Effective Method of Contraception
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: red cell hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: red cell survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Objective clinical benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Negative hepatitis C ribonucleic acid (HCV-RNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer lesion enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety as recorded by adverse-events and side-effects reports
Endpoint domain: Adverse events/effects
Primary endpoint: Fatigue measurement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Recording of frequency, severity and causality of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean GCSI-DD Before/After Treatment With Olanzapine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Mean Serum Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptoms relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pathologic METAVIR fibrosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogic Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Opinion of the investigator
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with peak pain scores less than 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sEPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum LDL cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cell yield from tumor samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Occupational exposure to dust
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Major Bleeding event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in the Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes in the fluorescein staining score (NEI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Diversity of Intestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety of Prostate Artery Embolization (PAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pennsylvania Shoulder Score (PENN)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Urine Bactericidal Activity (UBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum plasma concentration of glimepiride and dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure to glimepiride and dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interpersonal motor resonance (IMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Changes in Gross Motor Function Measurement (GMFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Change in Mullen's Scales of Early Learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of plasma small dense LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of missed doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percentage of delayed doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percentage of correct dosing period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Complete Sensory Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of medications used at follow-up compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal Hemoglobin Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Favorable Responses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of patients with severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retina measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: % Excess Weight Loss 4-6 Weeks After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Excess Weight Loss 12 Months After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination of N positive vs. N negative patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Preoperative localization of suspected positive nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Aggregate mean difference in tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle fiber area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle fiber types based on myosin heavy chain isoforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillaries per fiber area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of ETOR After Single Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of ETOR After Single Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of ETOR From Time 0 to Last (AUC0-last) After Single Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Participant Score on the WOMAC Visual Analog Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Percent of participants with confirmed or probable active TB
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of participants who permanently discontinue randomized study drug due to a treatment-related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Bronchitis Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Radiographic Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexuality function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients experiencing treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of paliperidone in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Natriuretic Brain Pro-peptid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Repeatability and reproducibility of CO-oximeter and sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production of missing enzyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who have quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Regulatory B cells functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Received appropriate care based on evidence-based treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Elimination half life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (RECIST Version 1.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Deoxygenated/oxygenated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: umbilical artery S/D ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain and tightness sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pancreatic infection
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of MKC1106-MT regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Average Daytime Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-last) of Uprifosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Uprifosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Total Body Clearance (CL/F) of Uprifosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural integrity of hybrid layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of dutasteride and tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With All-cause Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tumor stabilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUCo-inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: R15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: verifiable cocaine abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aberrant Behavior Checklist Irritability Subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bold Signal
Endpoint domain: General outcomes
Primary endpoint: Change in Tenofovir Diphosphate (TFV-DP) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Coated Platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Successful rate of first accurate placement of left-sided DLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Constipation severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Correlation between NIRS and DO2i
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agreement between SHAPE and pressure catheter measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Error between SHAPE and pressure catheter measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1C values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in glycaemic variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin grading evaluation of photodamage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Antibiotic Prescribing Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HbA1C Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Invasive arterial blood pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative 13-Carbon urea breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical Improvement (HAMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Albert's Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of Line Bisection Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median urinary iodine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Laryngectomy-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in serum iron (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: wound care outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in children's motor competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective overall response rate (PR+CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-esteem disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Subjects With Type 2 Diabetes Mellitus Who Have a Seroprotective Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: B-lines on chest ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Expiratory Volume after the first second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Collection of peripheral blood stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Prosthetic Valve Endocarditis
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of the response to the Standardized Goal Attainment Scaling menu for Hemophilia (GAS-Hem)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improved tolerance to enteral (tube) feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes of Symptom-Medication-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Derived American Shoulder and Elbow Society (ASES) Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Patient Derived American Shoulder and Elbow Society (ASES) Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Derived American Shoulder and Elbow Society (ASES) Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to clinical change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average change of Hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive total of procedural checklist items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compression hemostasis time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Grade of hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Total Clinical Signs and Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 meter walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 second up to sit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vascularity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: percentage of data correctly transmitted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in steady-state plasma concentration of cyclosporine and tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Functional Status at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline Back Range of Motion at 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Back Pain at 3 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Echocardiographic response of absolute increase of ≥5% in LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Echocardiographic response of ≥15% reduction in LVESV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical response at the early follow-up visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned healthcare utilisation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Foot posture index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal tolerated doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IIEF - Erectile Function domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stress hormones in serum cortisol and copeptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rate of infant acceptance of nutritional supplement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in infant consumption of nutritional supplement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level: VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Minutes of Sedentary Behavior, Light Physical Activity, and Moderate-to-vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relationship Between Total Fat Accumulation and Change in Sedentary Behavior - Visceral Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relationship Between Total Fat Accumulation and Change in Sedentary Behavior - Adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relationship Between Total Fat Accumulation and Change in Sedentary Behavior - Body Fat (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes